Quantcast
Home > Quotes > ABUS

Arbutus Biopharma Corporation Common Stock (ABUS) Quote & Summary Data

ABUS 
$4.39
*  
0.01
0.23%
Get ABUS Alerts
*Delayed - data as of Dec. 10, 2018 13:06 ET  -  Find a broker to begin trading ABUS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ABUS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.37 / $ 4.40
1 Year Target
5.25
Today's High / Low
$ 4.54 / $ 4.31
Share Volume
112,928
50 Day Avg. Daily Volume
441,045
Previous Close
$ 4.40
52 Week High / Low
$ 12.60 / $ 4.01
Market Cap
243,545,062
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.51
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.54

Intraday Chart

Shares Traded

Share Volume:
112,928
50 Day Avg. Daily Volume:
441,045

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.51

Trading Range

The current last sale of $4.39 is 9.48% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.54 $ 12.60
 Low: $ 4.31 $ 4.01

Company Description (as filed with the SEC)

1. Business Overview We are a publicly traded (Nasdaq Global Market: ABUS) therapeutic solutions company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection. To pursue our strategy of developing a curative combination regimen, we have assembled an HBV pipeline consisting of multiple drug candidates with differing and complementary mechanisms of action (MOA). In addition, we have a lipid nanoparticle delivery (LNP) platform with broad applications that extend beyond HBV, and related to the LNP platform we have a royalty entitlement on a drug that may be approved later in 2018. These assets have the potential to provide significant additional capital to fund our HBV development. HBV represents a significant unmet medical need and is the cause of the most common serious liver infection in the world.  ... More ...  


Risk Grade

Where does ABUS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.39
Open Date:
Dec. 10, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info